Prescriber's Guide to Lasmiditan


In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists.

This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice. 

Complete to Unlock Resource
SAP Partner Banner